Literature DB >> 19800151

[Conventional influenza vaccination compared to MF59 adjuvanted subunit vaccine].

María Amparo Torrecilla Rojas1, Miguel Pedregal González, Fermín García Rodriguez, Josefa Ruiz Fernández.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19800151      PMCID： PMC7022087          DOI： 10.1016/j.aprim.2009.06.008

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  20 in total

1.  Comparison of three different influenza vaccines in institutionalised elderly.

Authors:  V Baldo; T Menegon; C Bonello; A Floreani; R Trivello
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

Review 2.  MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.

Authors:  Joan Puig Barberà; David González Vidal
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

3.  Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.

Authors:  Filippo Ansaldi; Sabrina Bacilieri; Paolo Durando; Laura Sticchi; Laura Valle; Emanuele Montomoli; Giancarlo Icardi; Roberto Gasparini; Pietro Crovari
Journal:  Vaccine       Date:  2008-02-01       Impact factor: 3.641

Review 4.  [Influenza vaccine].

Authors:  Taisuke Horimoto; Shin Murakami; Yoshihiro Kawaoka
Journal:  Nihon Rinsho       Date:  2008-10

5.  Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly.

Authors:  F Pregliasco; C Mensi; W Serpilli; L Speccher; P Masella; A Belloni
Journal:  Aging (Milano)       Date:  2001-02

6.  Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy.

Authors:  A Iob; G Brianti; E Zamparo; T Gallo
Journal:  Epidemiol Infect       Date:  2005-08       Impact factor: 2.451

7.  Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients.

Authors:  G Gabutti; M Guido; P Durando; A De Donno; M Quattrocchi; S Bacilieri; F Ansaldi; S Cataldini; P G Chiriacò; M De Simone; S Minniti; L Sticchi; R Gasparini
Journal:  J Int Med Res       Date:  2005 Jul-Aug       Impact factor: 1.671

8.  Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons.

Authors:  M Minutello; F Senatore; G Cecchinelli; M Bianchi; T Andreani; A Podda; P Crovari
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

9.  Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.

Authors:  B R Ruf; K Colberg; M Frick; A Preusche
Journal:  Infection       Date:  2004-08       Impact factor: 3.553

10.  Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

Authors:  S Squarcione; S Sgricia; L R Biasio; E Perinetti
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.